**This article has been corrected:** The authors requested the replacement of Figure 4E and Table 1. Figure 4E (ciRs-6+miR-nc) was quite similar to Supplementary Figure 1D (si-3 in T24 cells) and was slightly updated. Changes of Table 1 are done to correct the statistical mistakes.

These corrections do not change the content of the publication and do not affect the conclusion of this research. The authors apologize for the unintentional mistakes.

The corrected Figure and Table are provided below.

![**miR-653 rescues the tumor suppressive effect of ciRs-6 in bladder cancer.** (**E**) Clone formation assays were used to evaluate clone forming ability.](aging-12-102885-g001){#f4}

###### Relationship between ciRs-6 level and clinical characteristics in bladder cancer.

  ----------------------------- -------------- -------------------------- -------- ------- ---------
  **Total**                     **Patients**   **Expression of ciRs-6**                    
  **High**                      **Low**        **p**                                       
  **Age(mean)**                 50             47.931                     52.069   0.395   
  **Gender**                                                                               
                                Male           45                         22       23      0.753
                                Female         13                         7        6       
  **Tumor stage**                                                                          
                                Tis/Ta/T1      31                         22       9       \<0.001
                                T2             17                         7        10      
                                T3/T4          10                         0        10      
  **Grade**                                                                                
                                High           20                         5        15      0.006
                                Low            38                         24       14      
  **Number of tumors**                                                                     
                                Solitary       41                         23       18      0.149
                                Multiple       17                         6        11      
  **Lymph node metastasis**                                                                
                                Negative       23                         13       10      0.421
                                Positive       35                         16       19      
  **Follow-up (month, mean)**   33.23          33.00                      33.45    0.047   
  ----------------------------- -------------- -------------------------- -------- ------- ---------
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